Santarus, Inc. (NASDAQ:SNTS.DL)

CAPS Rating: No stars

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar markmark69 (< 20) Submitted: 2/27/2013 1:51:16 PM : Outperform Start Price: $13.27 SNTS.DL Score: +119.00

I've owned over 1k shares of SNTS for almost 3yrs. Has several promsing Phase III products in its pipeline. Often overlooked are its cash agreements with Merck and GSK.

Featured Broker Partners


Advertisement